Visible-light-sensitive titanium dioxide nanoplatform for tumor-responsive Fe2+ liberating and artemisinin delivery

Huijuan Zhang; Hongling Zhang; Xing Zhu; Xiaoge Zhang; Qianqian Chen; Jianjiao Chen; Lin Hou; Zhenzhong Zhang

doi:10.18632/oncotarget.17639

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Visible-light-sensitive titanium dioxide nanoplatform for tumor-responsive Fe2+ liberating and artemisinin delivery

Huijuan Zhang, Hongling Zhang, Xing Zhu, Xiaoge Zhang, Qianqian Chen, Jianjiao Chen, Lin Hou and Zhenzhong Zhang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:58738-58753. https://doi.org/10.18632/oncotarget.17639

Metrics: PDF 2152 views | HTML 2643 views | ?

Abstract

Huijuan Zhang1,2,3, Hongling Zhang1,2,3, Xing Zhu1, Xiaoge Zhang1, Qianqian Chen1, Jianjiao Chen1, Lin Hou1,2,3 and Zhenzhong Zhang1,2,3

1School of Pharmaceutical Sciences, Zhengzhou University, Henan Province, Zhengzhou, China

2Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Henan Province, Zhengzhou, China

3Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Zhengzhou, China

Correspondence to:

Zhenzhong Zhang, email: [email protected]

Lin Hou, email: [email protected]

Keywords: Fe²⁺-dependent drug, visible-light-sensitive ROS production, tumor-responsive Fe²⁺ liberating

Received: October 06, 2016 Accepted: April 16, 2017 Published: May 05, 2017

ABSTRACT

Artemisinin is a kind of Fe²⁺-dependent drugs. Artemisinin and Fe²⁺ co-transport systems can improve its anti-tumor effect. In this study, a visible light-sensitive nanoplatform (HA-TiO₂-IONPs/ART) was developed. Detailed investigation demonstrated that HA-TiO₂-IONPs/ART could realize Fe²⁺ and artemisinin synchronous co-delivery and tumor-responsive release. This feature enhanced the anti-tumor efficiency of artemisinin significantly. In vitro results proved that hyaluronic acid modification could improve the biocompatibility, dispersion stability and cytophagy ability of nanocarriers. Furthermore, this drug delivery system could generate reactive oxygen species under visual light irradiation. In vitro and in vivo experiments demonstrated that HA-TiO₂-IONPs/ART combining with laser irradiation displayed the best anti-tumor efficacy. This study affords a promising idea to improve the curative efficiency of artemisinin analogs for cancer therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17639

Publication Alerts

Research Papers:

Visible-light-sensitive titanium dioxide nanoplatform for tumor-responsive Fe2+ liberating and artemisinin delivery

Abstract